IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 02:59:59 2024-04-25 am EDT			5-day change	1st Jan Change
8.75 ^GBX	0.00%		0.00%	-30.00%

Apr. 15	Ixico inks supply agreement with Life Molecular Imaging for Neuraceq	AN
Apr. 15	IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer	CI

IXICO : to Present at Innovation Forum

February 10, 2020 at 04:18 am EST

RNS Reach Story

Go to market news section

IXICO plc - IXI

IXICO to Present at Innovation Forum

Released 09:11 10-Feb-2020

RNS Number : 4717C

IXICO plc

10 February 2020

IXICO plc

('IXICO' or the 'Company')

IXICO to Present at the Annual Shares Magazine/Cenkos Growth and Innovation Forum

on 11^th February 2020

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that the Company will be attending and presenting at the Shares Magazine/Cenkos Growth and Innovation Forum on Tuesday, 11 February 2020 at the London Business Design Centre.

Giulio Cerroni, IXICO's Chief Executive Officer, will be attending the event and presenting at 12:15pm GMT in the Flowers Room.

Shares Magazine/Cenkos Growth and Innovation Forum:

Presentation: 12:15 PM GMT, 11 February 2020, Flowers Room

Exhibition: 09:00 AM - 5:00 PM GMT, 11 February 2020, Booth 25

London - Business Design Centre, London N1 52 Upper Street, Islington

The Shares Magazine/Cenkos Growth and Innovation Forum is one of the UK's major growth and technology focussed investment shows connecting investment experts, fund managers, company executives from fast-growing and technology-led London-listed companies.

For further information please contact:

IXICO plc	+44 (0) 20 3763 7498
Alison Howie, Chief Product Officer

Optimum Strategic Communications	+44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Manel Mateus
IXICO@optimumcomms.com

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available onwww.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAVBLBFBLLEBBV

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

IXICO to Present at Innovation Forum - RNS

Attachments

Original document
Permalink

Disclaimer

IXICO plc published this content on 10 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 February 2020 09:17:03 UTC

Latest news about IXICO plc

Ixico inks supply agreement with Life Molecular Imaging for Neuraceq	Apr. 15	AN
IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer	Apr. 15	CI
Ixico inks collaboration with IMEKA Solutions	Apr. 03	AN
IXICO plc Announces Collaboration Agreement with IMEKA Solutions Inc. to Provide Access to Imeka's Suite of Services for White Matter Imaging deployed in Alzheimer's Disease and Multiple Sclerosis Clinical Trials, Amongst Other CNS Indications	Apr. 03	CI
Ixico shares fall 20% as revenue to decline, hit by delays to projects	Mar. 13	AN
AIM WINNERS & LOSERS: Woodbois rises as plots Mozambique exit	Mar. 13	AN
FTSE 100 slips but CAC and DAX hit record highs	Mar. 13	AN
Ixico CEO Cerroni to retire by end of 2024; starts succession search	Jan. 12	AN
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024	Jan. 12	CI
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024	Jan. 12	CI
Transcript : IXICO plc, 2023 Earnings Call, Dec 05, 2023	Dec. 05
EARNINGS AND TRADING: Ixico revenue falls, Solid State boosts profit	Dec. 05	AN
IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 05	CI
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees	23-10-05	CI
EARNINGS AND TRADING: Barkby revenue dips; Ixico hurt by trial delays	23-09-29	AN
IXICO plc Provides Earnings Guidance for the Full Year of 2023	23-09-29	CI
Andrada raises GBP7.7 million; Ixico signs contract	23-07-18	AN
IXICO plc Announces Contract Win for A Phase 3 Progressive Supranuclear Palsy Study	23-07-18	CI
IXICO Receives New GBP2 Million Imaging Services Contract	23-06-14	MT
Ixico wins Huntington's disease contract worth GBP2 million	23-06-14	AN
IXICO plc Announces Contract Win in Huntington's Disease	23-06-14	CI
Transcript : IXICO plc, H1 2023 Earnings Call, May 23, 2023	23-05-23
Ixico shares drop as firm swings to interim loss on cancelled trials	23-05-23	AN
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP3.2M	23-05-23	MT
Earnings Flash (IXI.L) IXICO Reports Fiscal H1 Loss GBX-1.50	23-05-23	MT

Chart IXICO plc

Duration

Period

More charts

Company Profile

IXICO plc is a United Kingdom-based company that provides specialist data analytics services to the global biopharmaceutical industry. The services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. The outputs from the data analysis are used to enhance patient selection, monitor drug safety, and assess clinical efficacy of the drug under development. It offers a range of services, such as drug development analytics, imaging operations, post-marketing, and post-marketing. It offers end to end services, including trial design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. It offers a range of clinical trial imaging analysis tools, including radiological reads, structural and advanced magnetic resonance imaging (MRI). Its specialist data analytics services identify and measure biomarkers from brain scans and wearable biosensors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for IXICO plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IXICO PLC	-30.00%	5.26M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.24%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research